Evotec SE Stock

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 11:39:20 2024-06-24 EDT 5-day change 1st Jan Change
8.59 EUR +3.12% Intraday chart for Evotec SE +13.03% -59.63%

Financials

Sales 2024 * 883M 948M 1.29B Sales 2025 * 1.04B 1.11B 1.52B Capitalization 1.52B 1.64B 2.23B
Net income 2024 * -28M -30.06M -41.02M Net income 2025 * 31M 33.29M 45.41M EV / Sales 2024 * 1.98 x
Net Debt 2024 * 227M 244M 333M Net Debt 2025 * 186M 200M 273M EV / Sales 2025 * 1.65 x
P/E ratio 2024 *
-55 x
P/E ratio 2025 *
32.4 x
Employees 5,055
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.12%
1 week+13.03%
Current month-0.75%
1 month-2.88%
3 months-36.95%
6 months-59.19%
Current year-59.63%
More quotes
1 week
7.34
Extreme 7.335
8.88
1 month
7.22
Extreme 7.215
9.32
Current year
7.22
Extreme 7.215
21.42
1 year
7.22
Extreme 7.215
24.44
3 years
7.22
Extreme 7.215
45.83
5 years
7.22
Extreme 7.215
45.83
10 years
2.42
Extreme 2.42
45.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19-06-18
Director of Finance/CFO 51 23-02-06
Chief Operating Officer 54 12-04-30
Members of the board TitleAgeSince
Chief Executive Officer 61 19-06-18
Director/Board Member 56 19-06-18
Chairman 63 14-06-16
More insiders
Date Price Change Volume
24-06-24 8.59 +3.12% 888,126
24-06-21 8.33 -0.30% 3,027,218
24-06-20 8.355 +13.91% 3,156,472
24-06-19 7.335 -2.65% 598,980
24-06-18 7.535 -0.86% 1,050,669

Delayed Quote Xetra, June 24, 2024 at 11:39 am

More quotes
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.59 EUR
Average target price
20.79 EUR
Spread / Average Target
+142.03%
Consensus